China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai Duoning Biotechnology Co., Ltd, with the goal of strengthening the development of its mRNA industrialization platform. The collaboration aims to enhance the production capabilities and regulatory compliance of mRNA vaccines and drugs. No financial details were disclosed.
CATUG Bio’s GMP-Compliant mRNA Base
CATUG Bio has recently inaugurated its GMP-compliant mRNA production base in Wuhan. This state-of-the-art facility enables an end-to-end production process flow, covering plasmid preparation, mRNA synthesis, lipid nanoparticle (LNP) delivery, and final product filling. The domestically leading production line is designed to meet GMP manufacturing standards in both China and the US, positioning CATUG Bio to provide high-quality mRNA vaccines and drugs.
Future Outlook
The partnership with Shanghai Duoning Biotechnology underscores CATUG Bio’s commitment to advancing its mRNA industrialization platform. By leveraging the combined expertise of both companies, CATUG Bio aims to enhance its production capabilities and regulatory compliance, ultimately supporting the development and commercialization of mRNA-based therapies.-Fineline Info & Tech
